Cytosorbents EBIT per Share
The EBIT per Share of Cytosorbents (CTSO) as of Oct 25, 2026 is -1.91 USD. In the previous year, EBIT per Share was -7.68 USD — a change of -75.17% (higher).
Get this data via API
Financial Data API
EBIT per Share
-1.91USD
YoY
-75.17%
Last updated:
The Cytosorbents EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | -27.41USD | +144.61% |
| est | -11.21USD | +5.41% |
| est | -10.63USD | +9.54% |
| est | -9.70USD | +21.24% |
| est | -8.00USD | +319.82% |
| -1.91USD | -75.17% | |
| -7.68USD | -46.33% | |
| -14.31USD | -1.32% | |
| -14.50USD | +38.59% | |
| -10.46USD | +109.83% | |
| -4.99USD | -56.16% | |
| -11.37USD | +10.93% | |
| -10.25USD | +49.80% | |
| -6.84USD | -27.42% | |
| -9.43USD | +23.67% | |
| -7.63USD | +27.77% | |
| -5.97USD | -32.77% | |
| -8.88USD | +2,167.76% | |
| -0.39USD | -96.80% | |
| -12.25USD | +15.44% | |
| -10.61USD | +1,172.84% | |
| -0.83USD | -70.12% | |
| -2.79USD | -8.86% | |
| -3.06USD | -95.02% | |
| -61.50USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cytosorbents Stock analysis
Frequently Asked Questions about Cytosorbents stock
EBIT per Share of Cytosorbents is -1.91 USD in 2025.
EBIT per Share of Cytosorbents changed from -7.68 USD to -1.91 USD, representing a -75.17% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Cytosorbents since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Cytosorbents
All Key Metrics — Cytosorbents
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth